ARCH Venture Partners

ARCH Venture Partners

A venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease.

ARCH Venture Partners is a venture capital firm in Illinois that focuses on life science discoveries to prevent, detect and cure disease. Founded 1986 in Chicago, Illinois, United States by Clinton Bybee, Keith Crandell, Robert Nelsen and Steven Lazarus, it invests in early stage ventures, seed, series B, series A, series C, and post-IPO equity. Its portfolio companies include Volastra Therapeutics, Sonoma BioTherapeutics, Vizgen, EQRx, and Omniome. As of April 2020, ARCH Venture Partners has made 321 investments. Their most recent investment was on February 11, 2020, when Volastra Therapeutics raised $12M. ARCH Venture Partners has had 69 exits, the most notable of which include Twist Bioscience, Alnylam Pharmaceuticals, and Juno Therapeutics. The company has raised 10 funds, their latest being ARCH Venture Fund X. This fund was announced on October 25, 2019 and raised a total of $635.8M.

Timeline

1986

Founded

Funded Companies

Company
Description
Website
Industry
Location

A DNA synthesis company using a next-generation silicon-based technology platform.

Grail is a biotechnology company headquartered in Menlo Park, California that was founded as a spinoff of Illumina Inc and initially headed by Jeffrey Huber in 2016, focused on making a medical device that can detect early stage cancer.

Designs and manufactures nanotechnology materials to improve display color performance and batteries

A biotechnology company developing drugs and treatments to diminish negative health effects associated with aging.

Nebula Genomics is a genetics company developing a platform for individuals to get their personal genome sequenced, and then enable them to store and control that information through cryptographic encryption on the blockchain.

A company developing gene therapies for the treatment of genetic diseases and cancer.

A biopharmaceutical company developing neurobehavioural therapeutic treatments using artificial intelligence and clinical neuroscience.

Sage Therapeutics is a biopharmaceutical company founded by Douglas Covey and Steven Paul in 2010 and headquartered in Cambridge, Massachusetts focused on the discovery and development of medicines to address central nervous system disorders.

A bioinformatics company in San Francisco building data collection methods and databases that will enable machine learning algorithms in healthcare. It was founded in 2018.

A synthetic biology company using CRISPR to develop a portfolio of genetic medicines.

A Cambridge, MA - based startup that uses gene editing tech for xenotransplantation procedures in the medical industry.

A biotechnology company with a focus on pharmaceuticals that treat liver and gastrointestinal diseases. It was founded in 2014 and is located in San Diego, California.

A biopharmaceutical company with a focus on developing and manufacturing vaccines. It was founded in 2001 and has headquarters in Cambridge, Massachusetts.

A biotechnology company using photosynthetic organisms to make renewable solutions.

A genetic medicines company in Massachusetts that focuses on patients suffering from rare genetic diseases.

Crystal IS manufactures high-performance deep UV (UVC) LEDs for water and surface disinfection, monitoring, and sterilization applications in a variety of industries.

Aira is a computer vision connected devices virtual reality (VR) and augmented reality (AR) company developing tools for the visually impaired. Aira.IO is a wearable device to help the visually impaired gain more mobility and independence.

Luna DNA is company providing a marketplace for genetic data using blockchain based data storage.

Juno Therapeutics is a Biopharmaceutical company owned by Celgene.

A pharmaceutical company engaged in the discovery, development and commercializtion of antibacterials for the treatment of infections

74 Results
Page 1 of 3
Results per page:
Powered by Golden Research Engine

Associated investment funds

Investment Fund
Total offering (USD)
Total sold (USD)
Location
Date signed
250,000,000
April 23, 2014
450,000,000
November 18, 2016
600,000,000
October 26, 2018
400,000,000
March 17, 2016
600,000,000
October 26, 2018
6 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Amber Lu

Employee

Joshua White

Advisor

Keith Gillard

Board member

Michael Knapp

Employee

Mike Slawson

Employee

Vu Nguyen

Investor

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

Epirium Bio

EQRx

Omniome

Sonoma BioTherapeutics

Transcenta

Vizgen

Volastra Therapeutics

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.